HOLON, Israel, Feb. 4, 2025
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a
clinical-stage cancer immunotherapy company and a pioneer in
computational target discovery, today announced that
management will participate in a fireside chat at the Oppenheimer
35th Annual Healthcare Life Sciences Conference which will take
place virtually on February 11, 2025
at 8am ET.
A live webcast of the fireside chat will be available on the
Investor Relations section of Compugen's website at
www.cgen.com. A replay will be available following the live
event.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery platform (UnigenTM) to identify
new drug targets and biological pathways for developing cancer
immunotherapies. Compugen has two proprietary product candidates in
Phase 1 development: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a
PD-1/TIGIT bispecific antibody where the TIGIT component is derived
from Compugen's clinical stage anti-TIGIT antibody, COM902, is in
Phase 3 development by AstraZeneca through a license agreement for
the development of bispecific and multispecific
antibodies. COM503, a potential first-in-class, high affinity
anti-IL-18 binding protein antibody, which is in Phase 1
development is licensed to Gilead. In addition, the Company's
therapeutic pipeline of early-stage immuno-oncology programs
consists of programs aiming to address various mechanisms of immune
resistance. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN
Company contact:
Yvonne
Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302367189.html
SOURCE Compugen Ltd.